{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:22:39Z","timestamp":1790504559173,"version":"4.1.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Imatinib mesylate has transformed the treatment for chronic myeloid leukemia (CML). The vast majority of patients obtain hematologic remission, with a low probability of progression of disease. Yet imatinib rarely cures CML, and current recommendations dictate lifelong treatment with imatinib. In this review we analyze the biology behind the failure of imatinib to fully eradicate CML. We review evidence that indicates that the leukemic stem cell for CML is inherently resistant to imatinib, and that imatinib treatment itself may enhance this resistance.<\/jats:p>","DOI":"10.1634\/theoncologist.2009-0297","type":"journal-article","created":{"date-parts":[[2010,2,3]],"date-time":"2010-02-03T03:58:06Z","timestamp":1265169486000},"page":"182-186","source":"Crossref","is-referenced-by-count":25,"title":["Why Doesn't Imatinib Cure Chronic Myeloid Leukemia?"],"prefix":"10.1093","volume":"15","author":[{"given":"Robert L.","family":"Redner","sequence":"first","affiliation":[{"name":"University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2010,2,2]]},"reference":[{"key":"2021122207232976300_R1","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","article-title":"Translation of the Philadelphia chromosome into therapy for CML","volume":"112","author":"Druker","year":"2008","journal-title":"Blood"},{"key":"2021122207232976300_R2","first-page":"270","article-title":"Advances in CML","volume":"5","author":"Goldman","year":"2007","journal-title":"Clin Adv Hematol Oncol"},{"key":"2021122207232976300_R3","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"2021122207232976300_R4","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1182\/blood-2004-02-0711","article-title":"Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha","volume":"104","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"key":"2021122207232976300_R5","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-04-2139","article-title":"Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate","volume":"11","author":"Cortes","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2021122207232976300_R6","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1182\/blood-2003-07-2575","article-title":"Molecular response to imatinib in late chronic-phase chronic myeloid leukemia","volume":"103","author":"Rosti","year":"2004","journal-title":"Blood"},{"issue":"suppl 1","key":"2021122207232976300_R7","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.leukres.2003.10.017","article-title":"Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission","volume":"28","author":"Mauro","year":"2004","journal-title":"Leuk Res"},{"key":"2021122207232976300_R8","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"2021122207232976300_R9","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1182\/blood.V112.11.187.187","article-title":"Is it possible to stop imatinib in patients with chronic myeloid leukemia? An update from a French pilot study and first results from the multicentre \u201cStop Imatinib\u201d (STIM) study","volume":"112","author":"Mahon","year":"2008","journal-title":"Blood"},{"key":"2021122207232976300_R10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"2021122207232976300_R11","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/ni1080","article-title":"Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity","volume":"5","author":"Hope","year":"2004","journal-title":"Nat Immunol"},{"key":"2021122207232976300_R12","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1532\/IJH97.05144","article-title":"Biology of normal and acute myeloid leukemia stem cells","volume":"82","author":"Dick","year":"2005","journal-title":"Int J Hematol"},{"key":"2021122207232976300_R13","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.4161\/cc.8.9.8217","article-title":"Stem-cell driven cancer: \u201cHands-off\u201d regulation of cancer development","volume":"8","author":"Vicente-Due\u00f1as","year":"2009","journal-title":"Cell Cycle"},{"key":"2021122207232976300_R14","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.2008.17.5745","article-title":"Chronic myeloid leukemia stem cells","volume":"26","author":"Kavalerchik","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122207232976300_R15","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1365-2141.2008.07197.x","article-title":"Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: Implications for the biology, management, and therapy of the disease","volume":"142","author":"Valent","year":"2008","journal-title":"Br J Haematol"},{"key":"2021122207232976300_R16","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/leu.2008.392","article-title":"The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence","volume":"23","author":"Bruns","year":"2009","journal-title":"Leukemia"},{"key":"2021122207232976300_R17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJM197308092890608","article-title":"Clonal origin of chronic myelocytic leukemia","volume":"289","author":"Barr","year":"1973","journal-title":"N Engl J Med"},{"key":"2021122207232976300_R18","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1073\/pnas.58.4.1468","article-title":"Clonal origin of chronic myelocytic leukemia in man","volume":"58","author":"Fialkow","year":"1967","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122207232976300_R19","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML","volume":"351","author":"Jamieson","year":"2004","journal-title":"N Engl J Med"},{"key":"2021122207232976300_R20","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"2021122207232976300_R21","doi-asserted-by":"crossref","first-page":"16616","DOI":"10.1073\/pnas.0908107106","article-title":"A progenitor cell origin of myeloid malignancies","volume":"106","author":"Haeno","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122207232976300_R22","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/nature03669","article-title":"Dynamics of chronic myeloid leukaemia","volume":"435","author":"Michor","year":"2005","journal-title":"Nature"},{"key":"2021122207232976300_R23","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ccr.2009.06.007","article-title":"Persistence of leukemia-initiating cells in a conditional knockin model of an imatinib-responsive myeloproliferative disorder","volume":"16","author":"Oravecz-Wilson","year":"2009","journal-title":"Cancer Cell"},{"key":"2021122207232976300_R24","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.4161\/cc.3.12.1331","article-title":"Pharmacokinetic resistance to imatinib mesylate: Role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib","volume":"3","author":"Burger","year":"2004","journal-title":"Cell Cycle"},{"key":"2021122207232976300_R25","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood-2005-10-4020","article-title":"Complex interaction of BCRP\/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression","volume":"108","author":"Nakanishi","year":"2006","journal-title":"Blood"},{"key":"2021122207232976300_R26","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/sj.leu.2404638","article-title":"Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells","volume":"21","author":"Brendel","year":"2007","journal-title":"Leukemia"},{"key":"2021122207232976300_R27","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1182\/blood-2006-02-003145","article-title":"Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate","volume":"108","author":"Jordanides","year":"2006","journal-title":"Blood"},{"key":"2021122207232976300_R28","doi-asserted-by":"crossref","first-page":"6832","DOI":"10.1158\/0008-5472.CAN-04-1936","article-title":"Correlation between CXCR4 and homing or engraftment of acute myelogenous leukemia","volume":"64","author":"Monaco","year":"2004","journal-title":"Cancer Res"},{"key":"2021122207232976300_R29","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1158\/1535-7163.MCT-07-0042","article-title":"CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells","volume":"7","author":"Jin","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"2021122207232976300_R30","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1038\/sj.leu.2404224","article-title":"Hypoxia suppresses BCR\/Abl and selects imatinib-insensitive progenitors within clonal CML populations","volume":"20","author":"Giuntoli","year":"2006","journal-title":"Leukemia"},{"key":"2021122207232976300_R31","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/sj.leu.2403724","article-title":"Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli","volume":"19","author":"Holtz","year":"2005","journal-title":"Leukemia"},{"key":"2021122207232976300_R32","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/10245330500234195","article-title":"Evolving molecular therapy for chronic myeloid leukaemia\u2014are we on target?","volume":"10","author":"Copland","year":"2005","journal-title":"Hematology"},{"key":"2021122207232976300_R33","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/sj.leu.2403785","article-title":"Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro","volume":"19","author":"J\u00f8rgensen","year":"2005","journal-title":"Leukemia"},{"key":"2021122207232976300_R34","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1158\/0008-5472.CAN-06-2014","article-title":"Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment","volume":"67","author":"Holtz","year":"2007","journal-title":"Cancer Res"},{"key":"2021122207232976300_R35","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","article-title":"Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo","volume":"12","author":"Zhao","year":"2007","journal-title":"Cancer Cell"},{"key":"2021122207232976300_R36","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/nature07016","article-title":"PML targeting eradicates quiescent leukaemia-initiating cells","volume":"453","author":"Ito","year":"2008","journal-title":"Nature"},{"key":"2021122207232976300_R37","doi-asserted-by":"crossref","first-page":"5654","DOI":"10.1182\/blood-2007-11-126003","article-title":"Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data","volume":"111","author":"Hassane","year":"2008","journal-title":"Blood"},{"key":"2021122207232976300_R38","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1182\/blood-2004-10-4135","article-title":"The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells","volume":"105","author":"Guzman","year":"2005","journal-title":"Blood"},{"key":"2021122207232976300_R39","doi-asserted-by":"crossref","first-page":"e6257","DOI":"10.1371\/journal.pone.0006257","article-title":"Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia","volume":"4","author":"Hu","year":"2009","journal-title":"PLoS One"},{"key":"2021122207232976300_R40","doi-asserted-by":"crossref","first-page":"6546","DOI":"10.1158\/0008-5472.CAN-09-0605","article-title":"Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors","volume":"69","author":"Jagani","year":"2009","journal-title":"Cancer Res"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2009-0297","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2009-0297","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/15\/2\/182\/41843565\/oncolo_15_2_182.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/15\/2\/182\/41843565\/oncolo_15_2_182.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T08:31:27Z","timestamp":1640161887000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/15\/2\/182\/6399050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,1]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2010,2,2]]},"published-print":{"date-parts":[[2010,2,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2009-0297","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2010,2,1]]},"published":{"date-parts":[[2010,2,1]]}}}